Please use a PC Browser to access Register-Tadawul
Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy
Immutep Ltd Sponsored ADR IMMP | 2.76 | Delist |
Merck & Co., Inc. MRK | 117.09 | -0.02% |
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as first line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC).


